Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169280 · ClinicalTrials.gov registry record · Phase 1
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
A Phase 1 study of Glioma, Malignant and New Diagnosis Tumor, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06169280 is a Phase 1 study of Glioma, Malignant and New Diagnosis Tumor that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 20 participants, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06169280, a Phase 1 study of Glioma, Malignant and New Diagnosis Tumor, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the safety and feasibility of administering repeated doses of neural stem cell (NSC)-conditionally replicative adenovirus (CRAd)-survivin (S)-protomer (p)k7, in persons with newly diagnosed high grade glioma. The main questions it aims to answer are: * whether multiple doses of NSC-CRAd-S-pk7 are safe and feasible * how multiple doses of NSC-CRAd-S-pk7 influence tumor response, overall survival, time to tumor progression, and quality of life. Participants will: * undergo a biopsy to confirm high grade glioma, then receive the first dose of NSC-CRAd-S-pk7 into the brain * about 2 weeks later, undergo surgery to remove the tumor and receive the second dose of NSC-CRAd-S-pk7 into the brain * start chemoradiation about 2 weeks after surgery, then about 2 weeks later, receive the 3rd dose of NSC-CRAd-S-pk7 into the brain * four weeks later, at the end of chemoradiation, receive a fourth dose of NSC-CRAd-S-pk7 into the brain. * after radiation is finished, receive standard of care chemotherapy and tumor-treating fields. Two additional doses of NSC-CRAd-S-pk7 will be given every 4 weeks.
Conditions Studied
Interventions
- BIOLOGICAL NSC-CRAd-S-pk7
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06169280
The ClinicalTrials.gov registry entry for NCT06169280 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 19 other Glioma, Malignant trials with a reported enrollment target (68% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioma, Malignant appearing as the primary indexed condition, and to 1 intervention - of which NSC-CRAd-S-pk7 is the first listed.
NCT06169280 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06169280 about?
NCT06169280 is a clinical study titled "Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma". The goal of this clinical trial is to learn about the safety and feasibility of administering repeated doses of neural stem cell (NSC)-conditionally replicative adenovirus (CRAd)-survivin (S)-protomer (p)k7, in persons with newly diagnosed high grade glioma. The main questions it aims to answer are...
What is the current status of trial NCT06169280?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-27. Estimated completion is 2030-12-31.
What conditions does trial NCT06169280 study?
This clinical trial studies the following conditions: Glioma, Malignant, New Diagnosis Tumor.
What interventions are being tested in trial NCT06169280?
The interventions under investigation include: NSC-CRAd-S-pk7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06169280?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06169280 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
RECRUITING · Phase 1
-
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
-
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.